New Horizons in Complement-Mediated Kidney Diseases

CME Activities

• What Are the Patients' Unmet Needs in C3 Glomerulopathy? Clinical Pearls on Current Management and Future Perspectives
  Medscape Education, September 2023
  Do you know what the challenges are for patients and clinicians when managing C3 glomerulopathy, and what the role of emerging therapies is?
  0.50 CME

  0.50 ABIM MOC
• Controversies in the Role of Complement in Kidney Diseases: What Have We Learned From the Recent Meeting in Florence?
  Medscape Education, September 2023
  Did you know that both immunoglobulin A nephropathy and C3 glomerulopathy (C3G) have a variable long-term course, but untreated C3G has a generally poorer prognosis?
  0.50 CME

  0.50 ABIM MOC
• Finding the Needle in the Haystack: Following the Journey of a Patient With C3G
  Medscape Education, July 2023
  Are you aware of the burden of a delayed diagnosis for patients with C3G and do you know what to do to make an early and accurate C3G diagnosis?
  0.50 CME

  0.50 ABIM MOC
• A Detective Journey for Nephrologists: Practical Approaches to Differential Diagnosis of Rare Kidney Diseases
  Medscape Education, June 2023
  How able are you to distinguish C3G from IC-MPGN by looking at patients suspected of glomerular diseases presenting with overlapping signs and symptoms?
  0.50 CME

  0.50 ABIM MOC
• Classification and Nomenclature of IC-MPGN and C3G: A Spectrum of Diseases or Distinct Entities?
  Medscape Education, June 2023
  Discover expert tips from Dr Kavanagh on how to appropriately classify patients with C3G and IC-MPGN.
  0.50 CME

  0.50 ABIM MOC
• Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer
  Medscape Education, May 2023
  Did you know that, if left untreated, between 30% and 50% and up to 30% of patients with C3G and IgAN, respectively, will progress to end-stage kidney disease in 10 years?
  0.50 CME

  0.50 ABIM MOC
• Well Begun Is Half Done: Why and How Do We Assess Activity of the Complement Pathway in the Clinic?
  Medscape Education, April 2023
  Do you want to gain expert insights on the role of kidney biopsy and complement assays for complement-mediated kidney diseases?
  0.50 CME

  0.50 ABIM MOC
• Advances in the Management of Complement-Mediated Kidney Diseases: A Year in Review
  Medscape Education, December 2022
  Complement involvement in antibody- and non-antibody-mediated kidney diseases makes targeting complement activation an attractive therapeutic strategy.

• Management of C3 Glomerulopathy Today and Tomorrow: Navigating Novel Approaches to Improve Patient Care
  Medscape Education, July 2023
  From famine to feast, did you know that there are at least 5 complement inhibitors undergoing clinical development for patients with C3 glomerulopathy (C3G)?
  0.25 CME

  0.25 ABIM MOC
• Evidence of Complement Activation in IgAN and Therapeutic Implications
  Medscape Education, July 2023
  Did you know that immunoglobulin A nephropathy (IgAN) typically affects young adults, 50% of whom may develop kidney failure within 20 years after diagnosis?
  0.25 CME

  0.25 ABIM MOC
• The Renal Pathologist Perspective on the Diagnosis of IC-MPGN and C3G
  Medscape Education, June 2023
  Were you aware that the pathological workup of kidney biopsies in patients suspected of membranoproliferative glomerulonephritis (MPGN) spans a series of stained microscope specimens?
  0.25 CME

  0.25 ABIM MOC
• Diagnosis of IC-MPGN and C3G in a Renal Center for Complement-Targeted Therapeutics
  Medscape Education, June 2023
  Are you familiar with the recent reclassification of membranoproliferative glomerulonephritis (MPGN) into immune-complex (IC)-MPGN and complement-mediated MGPN or C3 glomerulopathy (C3G)?
  0.25 CME

  0.25 ABIM MOC